Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05786573 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv21
  2. Study sites: 10 to 7v20
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 44 to 10 · Primary completion date: Mar 14, 2026 to Jun 30, 2026 · Completion date: Jun 8, 2026 to Aug 31, 2026v19 Show 3 more changesShow less
    • Study sites: 44 to 10
    • Primary completion date: Mar 14, 2026 to Jun 30, 2026
    • Completion date: Jun 8, 2026 to Aug 31, 2026
  4. Study sites: 45 to 44v18
  5. Study sites: 47 to 45v17
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 48 to 47v16
  2. Study sites: 46 to 48v15
  3. Site details revised at 8 of 46 sitesv14
  4. Site details revised at 1 of 46 sitesv13
  5. Site details revised at 1 of 46 sitesv12
  6. Site details revised at 1 of 46 sitesv11
  7. Site details revised at 1 of 46 sitesv10
  8. Study sites: 21 to 46v9
  9. Study sites: 13 to 21v8
  10. Study sites: 11 to 13v7
  11. Primary endpoints revised (2) Study sites: 9 to 11v6 Show 1 more changeShow less
    • Study sites: 9 to 11

    See this version in full on ClinicalTrials.gov ↗

  12. Start date: Jun 23, 2023 to Sep 25, 2023 Study sites: 1 to 9 · Primary completion date: Dec 31, 2026 to Mar 14, 2026 · Completion date: Dec 31, 2027 to Jun 8, 2026v5 Show 3 more changesShow less
    • Study sites: 1 to 9
    • Primary completion date: Dec 31, 2026 to Mar 14, 2026
    • Completion date: Dec 31, 2027 to Jun 8, 2026
  13. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v4 Show 1 more changeShow less
    • Study sites: 0 to 1
  14. Re-verified, no change to tracked fieldsv3
  15. Start date: Apr 25, 2023 to Jun 23, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Trial Details
NCT Number NCT05786573
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Warm Autoimmune Hemolytic Anemia
Enrollment 134 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov